Not Signed In -
Deafness & Hearing Loss |
|
|
Clinical Trial: A Two Year Investigational Drug Study to Assess Weight Loss in Obese Patients
This study is not yet open for patient recruitment.
Verified by Merck August 2005
|
Purpose
A two year worldwide study in obese patients to assess the safety and tolerability as well as the effects of treatment with an investigational drug for weight loss on body weight and metabolic syndrome.
| Condition | Intervention | Phase |
|---|---|---|
| Obesity | Drug: An Investigational Drug for Weight Loss | Phase II |
MedlinePlus related topics: Obesity
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- Body Mass Index (BMI) between 30-43 kg/m2
Exclusion Criteria:
Location and Contact Information
Please refer to this study by ClinicalTrials.gov identifier NCT00131391
Toll Free Number 1-888-577-8839
Study chairs or principal investigators
Medical Monitor, Study Director, Merck
More Information
Study ID Numbers: 2005_034
Last Updated: August 17, 2005
Record first received: August 16, 2005
ClinicalTrials.gov Identifier: NCT00131391
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-08-23
Last Updated: August 17, 2005
Record first received: August 16, 2005
ClinicalTrials.gov Identifier: NCT00131391
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-08-23
email this page
print this page
bookmark this page
feedback on this page
